– Rilonacept pivotal Phase 3 trial in recurrent pericarditis met statistical significance for primary and all major secondary efficacy endpoints; sBLA […]
Reports record quarterly revenue of $87.5 millionOverall revenue grew 24% year-over-year, with organic growth of 19%Raises revenue guidance to $332-$340 […]